Navigation Links
Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board

owing topics:

  • highlights from the June 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO);
  • an update on the on-going Phase II clinical trial of the AE37 breast cancer vaccine;
  • the current state of the treatment of breast cancer and treatment trends;
  • treatment options for patients who express low levels of HER2;
  • a review of antibodies and vaccines in immunotherapy and the importance of CD4+ T cell activation by Ii-Key;
  • biomarkers and personalized medicine in cancer care and opportunities for the Ii-Key platform;
  • treatment options for triple-negative breast cancer; and
  • an update from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the potential for AE37.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulatio

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
2. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
3. Generex Announces Date of Annual Stockholders Meeting
4. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
5. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
6. Generex Secures Commitments for $3.6M Capital Raise
7. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
8. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
9. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
10. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
11. Averica Discovery Announces Winner of First Averica Award for Supercritical Fluid Chromatography (SFC)
Post Your Comments:
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the Company will issue a ... on Monday, August 18, 2014 for shareholders. Management has ... Monday, August 18, 2014 to discuss the company,s progress ... Anthony Hayes . Following prepared remarks, ...
(Date:7/23/2014)... NEW YORK , July 24, 2014 /PRNewswire/ ... and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX ... "IMNP."; "Immune" or "the Company"), announced a collaboration ... bullous pemphigoid last night at an event attended ... other interested parties. Lyfebulb is a health and ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Spherix Schedules Shareholder Update Call 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5
... FOREST, Ill., Oct. 7 Hospira, Inc.,(NYSE: HSP ... today announced that it will host a conference call ... 2008, at 8,a.m. Central time., The company will ... stock market open and the conference call., A ...
... Orthocrat Ltd., announced,today that the George Washington ... planning and digital templating,software solution., Orthopedic ... acetate,overlays to determine the size of prosthetic ... adoption of digital imaging,technologies for x-rays, TraumaCad ...
... CITY, Oct. 7 Great Basin Scientific, Inc., ... diagnostic solutions, today announced it had closed a ... in the,funding for this round., The new ... the spring of,2009 as it completes the design ...
Cached Biology Technology:George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 2George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 3Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding 2
(Date:7/24/2014)... Iyer, O.D., a low vision specialist at The University ... School, has been awarded a grant to help Harris ... eyeglasses, medication or surgery. , Even with corrective lenses, ... best. However, there are a variety of low vision ... help offset their vision loss. , Iyer is using ...
(Date:7/24/2014)... Atlantic Forest is a hotspot of biodiversity and one ... tree-frogs, and toads) in the world. However, current levels ... few years has been an increase in the description ... the advance of molecular techniques and availability of samples ... number of samples for molecular and morphological analysis, researchers ...
(Date:7/24/2014)... A yearlong study funded by the New Jersey ... J. Bloustein School of Planning and Public Policy at ... Sandy-affected towns are skeptical about the likelihood of community-based ... respondents, 45 percent indicated they were "pessimistic" or "very ... Superstorm Sandy would be rebuilt better than they were ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2A tiny new species of frog from Brazil with a heroic name 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... her research into single-cell organisms that affect oral health, ... molecular genetics at The University of Texas Health Science ... the 2011 American Society for Microbiology (ASM) Founders Distinguished ... made significant contributions to the society. Goldschmidt joined the ...
... The University of Pennsylvania, Dr. Ron Koder, assistant professor of ... of a team that devised a novel method for producing ... neuroglobin. He was recently awarded a three-year $1.3 million ... artificial blood that can be administered to injured troops on ...
... Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg ... the effort to wipe out some of the most ... large structural genomics centers, they,ve experimentally determined 500 three-dimensional ... pathogens, which could potentially lead to new drugs, vaccines ...
Cached Biology News:UTHealth professor to receive service award from American Society for Microbiology 2CCNY professor gets grant to develop 'artificial blood' 2Milestone in fight against deadly disease 2Milestone in fight against deadly disease 3
... EVO Clinical is Tecans open platform for ... quality, safety and performance in the clinical ... provided by flexible barcode reading and sample ... that the system complies with the IVD-Directive* ...
... cycler, flexible on your protocols, easy on your ... high sample throughput instrument at a highly affordable ... format: The truly user-friendly fully interchangeable block system ... of seconds without the need of any tools ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
... Tecans GenePaint system, which is based on ... steps required for performing in situ hybridization of ... key step in the study of gene expression, ... cells and tissues and can be used to ...
Biology Products: